Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC

Chenying Li, Lei Dong, Rui Su, Ying Bi, Ying Qing, Xiaolan Deng, Yile Zhou, Chao Hu, Mengxia Yu, Hao Huang, Xi Jiang, Xia Li, Xiao He, Dongling Zou, Chao Shen, Li Han, Miao Sun, Jennifer Skibbe, Kyle Ferchen, Xi Qin, Hengyou Weng, Huilin Huang, Chunxiao Song, Jianjun Chen, and Jie Jin

Disclosures: J.C. is a scientific founder of the Genovel Biotech Corp.

Contributions: C.L., R.S., J.J. and J.C. conceived the project and designed the research. C.L., R.S., Y.B., Y.Q., X.D., Y.Z., C.H., M.Y., H.H., X.J., X.L., X.H., D.Z., C.S., L.H., M.S., J.S., K.F., X.Q., H.W., H.H., C.S., and J.C. performed experiments and/or data analysis. L.D. performed the bioinformatics analysis. C.S., J.J. and J.C. contributed reagents/analytic tools and/or grant supports. C.L., R.S., J.J. and J.C. wrote the paper. All authors discussed the results and commented on the manuscript.